Compass Therapeutics Inc. (CMPX) NASDAQ
$1.98 (0.07) (-3.42%)
Market Cap: $282.06M
As of 03/28/24 04:00 PM EDT. Market closed.
Compass Therapeutics Inc. (CMPX)
NASDAQ
$1.98
(0.07) (-3.42%)
Market Cap: $282.06M
As of 03/28/24 04:00 PM EDT. Market closed.
compass therapeutics is an antibody discovery and development company focused on comprehensively drugging the tumor-immune synapse with combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. compass is industrializing antibody discovery and decentralizing biologic validation through a partnership-first mentality that leverages best-in-class technologies and ... read more
compass therapeutics is an antibody discovery and development company focused on comprehensively drugging the tumor-immune synapse with combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. compass is industrializing antibody discovery and decentralizing biologic validation through a partnership-first mentality that leverages best-in-class technologies and top-tier academic laboratories around the world. novel scientific insights are validated and explored deeply inside our labs before compass pursues the best proprietary combinations of therapeutics into human clinical trials. in 2015, compass quietly closed a $120mm series a financing to fund our ambitious plan to build a fully-integrated biopharmaceutical company from the ground up. our investors are among the most sophisticated venture capitalists in the industry who exemplify our philosophy of building long term economic value only by delivering therapeutics with meaningful efficacy beyond read less
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Bisker-Leib Vered | CHIEF EXECUTIVE OFFICER | Feb 08, 2024 | Option Exercise | $1.45 | 49,198 | 71,337 | 3,124,426 | Feb 09, 2024, 12:50 PM |
Schuetz Thomas J. | PRESIDENT | Feb 08, 2024 | Option Exercise | $1.45 | 44,782 | 64,934 | 6,570,566 | Feb 09, 2024, 12:49 PM |
Bisker-Leib Vered | Chief Executive Officer | Jan 09, 2024 | Option Exercise | $1.93 | 1,753,125 | 3,383,531 | 3,173,624 | Jan 10, 2024, 10:31 AM |
Schuetz Thomas J. | President of R&D | Jan 09, 2024 | Option Exercise | $1.93 | 637,500 | 1,230,375 | 6,615,348 | Jan 10, 2024, 10:31 AM |
Bisker-Leib Vered | Chief Operating Officer | Nov 17, 2023 | Option Exercise | $1.50 | 64,415 | 96,623 | 1,420,499 | Nov 21, 2023, 02:10 PM |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Nov 17, 2023 | Option Exercise | $1.50 | 44,025 | 66,038 | 5,977,848 | Nov 21, 2023, 02:08 PM |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Mar 10, 2023 | Buy | $3.37 | 10,000 | 33,700 | 6,021,873 | Mar 10, 2023, 01:34 PM |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Feb 27, 2023 | Buy | $3.98 | 20,000 | 79,600 | 6,011,873 | Feb 27, 2023, 11:39 AM |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Feb 15, 2023 | Buy | $3.86 | 20,000 | 77,200 | 5,991,873 | Feb 15, 2023, 10:47 AM |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Jan 31, 2023 | Buy | $4.05 | 20,000 | 81,000 | 5,471,873 | Jan 31, 2023, 10:14 AM |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Jan 24, 2023 | Buy | $4.19 | 20,000 | 83,800 | 5,451,873 | Jan 24, 2023, 10:49 AM |
Bisker-Leib Vered | Chief Operating Officer | Nov 25, 2022 | Sale | $4.36 | 2 | 9 | 1,060,414 | Nov 25, 2022, 04:41 PM |
Bisker-Leib Vered | Chief Operating Officer | Nov 23, 2022 | Sale | $4.30 | 9,569 | 41,147 | 1,060,416 | Nov 25, 2022, 04:41 PM |
Bisker-Leib Vered | Chief Operating Officer | Nov 22, 2022 | Sale | $4.19 | 14,929 | 62,553 | 1,069,985 | Nov 25, 2022, 04:41 PM |
Bisker-Leib Vered | Chief Operating Officer | Nov 21, 2022 | Sale | $4.34 | 16,035 | 69,592 | 1,084,914 | Nov 22, 2022, 04:15 PM |
Bisker-Leib Vered | Chief Operating Officer | Nov 18, 2022 | Sale | $4.40 | 6,226 | 27,394 | 1,107,175 | Nov 22, 2022, 04:15 PM |
ORBIMED ADVISORS LLC | Director | Nov 08, 2022 | Buy | $3.21 | 402,000 | 1,290,420 | 15,219,994 | Nov 10, 2022, 04:44 PM |
GORDON CARL L | Director | Nov 08, 2022 | Buy | $3.21 | 402,000 | 1,290,420 | 15,219,994 | Nov 10, 2022, 04:38 PM |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Sep 28, 2022 | Buy | $2.32 | 10,000 | 23,200 | 5,431,873 | Sep 28, 2022, 04:45 PM |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Sep 26, 2022 | Buy | $2.27 | 15,000 | 34,050 | 5,421,873 | Sep 27, 2022, 09:47 AM |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Sep 07, 2022 | Buy | $3.03 | 15,000 | 45,450 | 5,406,873 | Sep 08, 2022, 10:12 AM |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Sep 01, 2022 | Buy | $2.83 | 15,000 | 42,450 | 5,391,873 | Sep 01, 2022, 02:37 PM |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Aug 10, 2022 | Buy | $2.64 | 15,000 | 39,600 | 5,361,873 | Aug 10, 2022, 10:51 AM |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Aug 01, 2022 | Buy | $2.58 | 15,000 | 38,700 | 5,346,873 | Aug 02, 2022, 09:15 AM |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Jun 21, 2022 | Buy | $2.80 | 20,000 | 56,000 | 5,331,873 | Jun 21, 2022, 01:41 PM |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Jun 16, 2022 | Buy | $2.34 | 20,000 | 46,800 | 5,311,873 | Jun 17, 2022, 04:46 PM |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Jun 13, 2022 | Buy | $2.29 | 30,000 | 68,700 | 5,291,873 | Jun 13, 2022, 03:59 PM |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Jun 06, 2022 | Buy | $2.83 | 30,000 | 84,900 | 5,261,873 | Jun 07, 2022, 11:50 AM |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Jun 01, 2022 | Buy | $3.03 | 20,000 | 60,600 | 5,231,873 | Jun 01, 2022, 12:33 PM |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | May 26, 2022 | Buy | $3.04 | 20,000 | 60,800 | 5,211,873 | May 26, 2022, 02:58 PM |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | May 23, 2022 | Buy | $2.72 | 18,355 | 49,926 | 5,191,873 | May 24, 2022, 08:09 AM |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | May 17, 2022 | Buy | $2.47 | 20,215 | 49,931 | 5,173,518 | May 17, 2022, 03:17 PM |
GORDON CARL L | Director | May 13, 2022 | Buy | $2.49 | 30,722 | 76,498 | 14,817,994 | May 13, 2022, 05:48 PM |
GORDON CARL L | Director | May 12, 2022 | Buy | $2.35 | 97,094 | 228,171 | 14,787,272 | May 13, 2022, 05:48 PM |
GORDON CARL L | Director | May 11, 2022 | Buy | $1.79 | 64,700 | 115,813 | 14,690,178 | May 13, 2022, 05:48 PM |
ORBIMED ADVISORS LLC | Director | May 12, 2022 | Buy | $2.35 | 97,094 | 228,171 | 14,787,272 | May 13, 2022, 05:45 PM |
ORBIMED ADVISORS LLC | Director | May 11, 2022 | Buy | $1.79 | 64,700 | 115,813 | 14,690,178 | May 13, 2022, 05:45 PM |
ORBIMED ADVISORS LLC | Director | May 13, 2022 | Buy | $2.49 | 30,722 | 76,498 | 14,817,994 | May 13, 2022, 05:45 PM |
ORBIMED ADVISORS LLC | Director | May 06, 2022 | Buy | $1.63 | 10,200 | 16,626 | 14,510,319 | May 10, 2022, 06:21 PM |
ORBIMED ADVISORS LLC | Director | May 10, 2022 | Buy | $1.60 | 24,447 | 39,115 | 14,625,478 | May 10, 2022, 06:21 PM |
ORBIMED ADVISORS LLC | Director | May 09, 2022 | Buy | $1.56 | 90,712 | 141,511 | 14,601,031 | May 10, 2022, 06:21 PM |
GORDON CARL L | Director | May 10, 2022 | Buy | $1.60 | 24,447 | 39,115 | 14,625,478 | May 10, 2022, 06:19 PM |
GORDON CARL L | Director | May 09, 2022 | Buy | $1.56 | 90,712 | 141,511 | 14,601,031 | May 10, 2022, 06:19 PM |
GORDON CARL L | Director | May 06, 2022 | Buy | $1.63 | 10,200 | 16,626 | 14,510,319 | May 10, 2022, 06:19 PM |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | May 10, 2022 | Buy | $1.80 | 27,836 | 50,105 | 5,153,303 | May 10, 2022, 02:15 PM |
GORDON CARL L | Director | Nov 04, 2021 | Buy | $3.50 | 5,357,143 | 18,750,001 | 14,500,119 | Nov 08, 2021, 09:12 PM |
ORBIMED ADVISORS LLC | Director | Nov 04, 2021 | Buy | $3.50 | 5,357,143 | 18,750,001 | 14,500,119 | Nov 08, 2021, 09:06 PM |
Owner | Relationship | Date | Value($) |
Bisker-Leib Vered | CHIEF EXECUTIVE OFFICER | 02/08/2024 | 71,337 |
Schuetz Thomas J. | PRESIDENT | 02/08/2024 | 64,934 |
Bisker-Leib Vered | Chief Executive Officer | 01/09/2024 | 3,383,531 |
Schuetz Thomas J. | President of R&D | 01/09/2024 | 1,230,375 |
Bisker-Leib Vered | Chief Operating Officer | 11/17/2023 | 96,623 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 11/17/2023 | 66,038 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 03/10/2023 | 33,700 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 02/27/2023 | 79,600 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 02/15/2023 | 77,200 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 01/31/2023 | 81,000 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 01/24/2023 | 83,800 |
Bisker-Leib Vered | Chief Operating Officer | 11/25/2022 | 9 |
Bisker-Leib Vered | Chief Operating Officer | 11/23/2022 | 41,147 |
Bisker-Leib Vered | Chief Operating Officer | 11/22/2022 | 62,553 |
Bisker-Leib Vered | Chief Operating Officer | 11/21/2022 | 69,592 |
Bisker-Leib Vered | Chief Operating Officer | 11/18/2022 | 27,394 |
ORBIMED ADVISORS LLC | Director | 11/08/2022 | 1,290,420 |
GORDON CARL L | Director | 11/08/2022 | 1,290,420 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 09/28/2022 | 23,200 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 09/26/2022 | 34,050 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 09/07/2022 | 45,450 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 09/01/2022 | 42,450 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 08/10/2022 | 39,600 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 08/01/2022 | 38,700 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 06/21/2022 | 56,000 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 06/16/2022 | 46,800 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 06/13/2022 | 68,700 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 06/06/2022 | 84,900 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 06/01/2022 | 60,600 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 05/26/2022 | 60,800 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 05/23/2022 | 49,926 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 05/17/2022 | 49,931 |
GORDON CARL L | Director | 05/13/2022 | 76,498 |
GORDON CARL L | Director | 05/12/2022 | 228,171 |
GORDON CARL L | Director | 05/11/2022 | 115,813 |
ORBIMED ADVISORS LLC | Director | 05/12/2022 | 228,171 |
ORBIMED ADVISORS LLC | Director | 05/11/2022 | 115,813 |
ORBIMED ADVISORS LLC | Director | 05/13/2022 | 76,498 |
ORBIMED ADVISORS LLC | Director | 05/06/2022 | 16,626 |
ORBIMED ADVISORS LLC | Director | 05/10/2022 | 39,115 |
ORBIMED ADVISORS LLC | Director | 05/09/2022 | 141,511 |
GORDON CARL L | Director | 05/10/2022 | 39,115 |
GORDON CARL L | Director | 05/09/2022 | 141,511 |
GORDON CARL L | Director | 05/06/2022 | 16,626 |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 05/10/2022 | 50,105 |
GORDON CARL L | Director | 11/04/2021 | 18,750,001 |
ORBIMED ADVISORS LLC | Director | 11/04/2021 | 18,750,001 |
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
ORBIMED ADVISORS LLC | 18,791,422 | 0.84% | -15.97% | Other |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 9,880,000 | 0.03% | 54.86% | Other |
BLACKROCK INC. | 6,222,309 | 0.00025% | 4.16% | Other |
BLACKSTONE INC. | 6,189,551 | 0.04% | No change | Other |
VIVO CAPITAL, LLC | 3,556,023 | 0.45% | No change | Other |
GEODE CAPITAL MANAGEMENT, LLC | 1,992,028 | 0.00033% | 5.27% | Other |
BAKER BROS. ADVISORS LP | 1,557,630 | 0.03% | No change | Other |
RENAISSANCE TECHNOLOGIES LLC | 176,799 | 0.00043% | 559.7% | Other |
ALPS ADVISORS INC | 94,115 | 0.00154% | Exited | Other |
Period of Report: 12/31/2023
10-K/10-Q Filings: View